How great is the market potential of your product? How should you position your device to physicians, patients or caregivers? Which product features should you leverage in your communication strategy? What will persuade formulary committee members to recommend your product?
Our healthcare industry specialists have an unrivaled track record of providing great answers to these and similar questions. It’s why global healthcare companies such as Bayer HealthCare, Eli Lilly, Pfizer, and Sanofi-Aventis come to SKIM for conjoint analysis, maximum differential scaling, qualitative research and more.
Recently, we published a trilogy of biosimilars briefs where we discussed the importance of addressing three key questions in developing successful strategies. Click the button below to read our recent learnings based on biosimilars studies: